These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 8206492)
1. Treatment of early stage prostate cancer: conservative management--delayed therapy. Chodak GW Important Adv Oncol; 1994; ():241-4. PubMed ID: 8206492 [No Abstract] [Full Text] [Related]
2. [Established and new urological therapeutic options in the management of prostate carcinoma]. Michel MS; Trojan L; Knoll T; Bross S; Alken P Radiologe; 2003 Jun; 43(6):441-7. PubMed ID: 12827258 [TBL] [Abstract][Full Text] [Related]
3. Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy. Beyer DC; McKeough T; Thomas T Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1299-305. PubMed ID: 15817331 [TBL] [Abstract][Full Text] [Related]
4. Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Miyamoto H; Messing EM; Chang C Nat Clin Pract Oncol; 2005 May; 2(5):236-7. PubMed ID: 16264955 [No Abstract] [Full Text] [Related]
6. Early versus delayed hormonal therapy for prostate specific antigen only recurrence of prostate cancer after radical prostatectomy. Moul JW; Wu H; Sun L; McLeod DG; Amling C; Donahue T; Kusuda L; Sexton W; O'Reilly K; Hernandez J; Chung A; Soderdahl D J Urol; 2004 Mar; 171(3):1141-7. PubMed ID: 14767288 [TBL] [Abstract][Full Text] [Related]
7. Survival of men with clinically localized prostate cancer treated with prostatectomy, brachytherapy, or no definitive treatment: impact of age at diagnosis. Tward JD; Lee CM; Pappas LM; Szabo A; Gaffney DK; Shrieve DC Cancer; 2006 Nov; 107(10):2392-400. PubMed ID: 17041884 [TBL] [Abstract][Full Text] [Related]
8. Short-course androgen ablation combined with external-beam radiation therapy and low-dose-rate permanent brachytherapy in early-stage prostate cancer: a matched subset analysis. Sylvester J; Blasko JC; Grimm PD; Meier R; Cavanagh W Mol Urol; 2000; 4(3):155-9;discussion 161. PubMed ID: 11062369 [TBL] [Abstract][Full Text] [Related]
9. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy. Zietman AL; Thakral H; Wilson L; Schellhammer P J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206 [TBL] [Abstract][Full Text] [Related]
10. Retrospective comparison of external beam radiotherapy and radical prostatectomy in high-risk, clinically localized prostate cancer. Arcangeli G; Strigari L; Arcangeli S; Petrongari MG; Saracino B; Gomellini S; Papalia R; Simone G; De Carli P; Gallucci M Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):975-82. PubMed ID: 19395188 [TBL] [Abstract][Full Text] [Related]
11. [Surgical and medical treatment for localized prostate cancer]. Kawai K Gan To Kagaku Ryoho; 2007 Jul; 34(7):1002-5. PubMed ID: 17637535 [TBL] [Abstract][Full Text] [Related]
12. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Efstathiou JA; Skowronski RY; Coen JJ; Grocela JA; Hirsch AE; Zietman AL Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1302-8. PubMed ID: 18262732 [TBL] [Abstract][Full Text] [Related]
13. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. Halabi S; Vogelzang NJ; Ou SS; Small EJ J Urol; 2007 Feb; 177(2):531-4. PubMed ID: 17222627 [TBL] [Abstract][Full Text] [Related]
14. High-dose radiation employing external beam radiotherapy and high-dose rate brachytherapy with and without neoadjuvant androgen deprivation for prostate cancer patients with intermediate- and high-risk features. Vargas C; MartÃnez A; Galalae R; Demanes J; Harsolia A; Schour L; Nuernberg N; Gonzalez J Prostate Cancer Prostatic Dis; 2006; 9(3):245-53. PubMed ID: 16786040 [TBL] [Abstract][Full Text] [Related]
15. Prostate cancer (non-metastatic). Wilt T Clin Evid; 2003 Jun; (9):973-85. PubMed ID: 12967402 [No Abstract] [Full Text] [Related]
16. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. Siddiqui SA; Boorjian SA; Inman B; Bagniewski S; Bergstralh EJ; Blute ML J Urol; 2008 May; 179(5):1830-7; discussion 1837. PubMed ID: 18353378 [TBL] [Abstract][Full Text] [Related]
17. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime. Martinez AA; Demanes DJ; Galalae R; Vargas C; Bertermann H; Rodriguez R; Gustafson G; Altieri G; Gonzalez J Int J Radiat Oncol Biol Phys; 2005 Aug; 62(5):1322-31. PubMed ID: 16029788 [TBL] [Abstract][Full Text] [Related]
18. [Maximal androgen blockade and maximal androgen blockade combined with 125I brachytherapy for prostatic cancer]. Su Y; Yao MY; Yuan Z; Yang JJ; Liu J; Hu XN Zhonghua Nan Ke Xue; 2003 Sep; 9(6):434-5. PubMed ID: 14574808 [TBL] [Abstract][Full Text] [Related]
19. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. Tsai HK; D'Amico AV; Sadetsky N; Chen MH; Carroll PR J Natl Cancer Inst; 2007 Oct; 99(20):1516-24. PubMed ID: 17925537 [TBL] [Abstract][Full Text] [Related]
20. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy. D'Amico A BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]